World Pharma News Digest - 21.09.2009

0 views
Skip to first unread message

Ruslan David

unread,
Sep 21, 2009, 4:46:16 AM9/21/09
to worldph...@googlegroups.com
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 
Bayer Schering Pharma announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar® (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin™ - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany. 
Read more... 
http://www.worldpharmanews.com/content/view/944/1/
 
U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine 
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. 
Read more... 
http://www.worldpharmanews.com/content/view/943/1/
 
The bacterial challenge - time to react 
There is a need for more development of antibiotics that are effective against multidrug-resistant bacteria. That is the conclusion of a new report prepared jointly by the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMEA) with contributions from the international network Action on Antibiotic Resistance (ReAct). 
Read more... 
http://www.worldpharmanews.com/content/view/942/1/
 
How Oncologists Use the Internet and Other Technologies 
Oncologists are more likely than the overall population of U.S. physicians to visit pharmaceutical, biotech, and device corporate and product websites on a regular basis, according to pharmaceutical and healthcare market research company Manhattan Research. In fact, almost seventy percent of oncologists visit product websites monthly or more often.
Read more... 
http://www.worldpharmanews.com/content/view/941/1/
 
Novartis investigational bronchodilator QAB149 compared to tiotropium 
Novartis has announced results from Phase III trials showing QAB149 (indacaterol), an investigational once-daily bronchodilator for chronic obstructive pulmonary disease (COPD), significantly improves lung function[3] and provides a significant reduction in breathlessness[1] compared to tiotropium, a current treatment option. 
Read more... 
http://www.worldpharmanews.com/content/view/940/1/
 
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product 
Amgen (Nasdaq: AMGN) has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it. 
Read more... 
http://www.worldpharmanews.com/content/view/939/1/
 
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients 
Eli Lilly and Company (NYSE: LLY) has unveiled a new operating model and announced a series of changes to speed medicines from its pipeline to patients. To help achieve this goal, the company will establish a Development Center of Excellence to streamline and accelerate late-stage development of new medicines, and will reorganize its pharmaceutical business into four business units that will operate alongside the Elanco animal health business unit. 
Read more... 
http://www.worldpharmanews.com/content/view/938/1/
 
Two new studies report increased survival rates in Tamiflu-treated patients 
Tamiflu (oseltamivir) demonstrated significantly improved survival rates in patients with the highly pathogenic H5N1 influenza (avian flu) and severe cases of seasonal influenza, according to two new studies presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.(1,2) 
Read more... 
http://www.worldpharmanews.com/content/view/937/1/
 
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent 
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. 
Read more... 
http://www.worldpharmanews.com/content/view/936/1/
 
PharmaNews.eu / Latest News
 
 
 
 
Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix®
http://www.pharmanews.eu/bms/323-global-study-provides-additional-information-about-an-intensified-dose-regimen-of-plavixr
 
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
http://www.pharmanews.eu/lilly/322-lilly-unveils-blueprint-for-speeding-innovative-medicines-to-patients
 
Initial results from first clinical trial of GSK's H1N1 adjuvanted vaccine
http://www.pharmanews.eu/gsk/321-initial-results-from-first-clinical-trial-of-gsks-h1n1-adjuvanted-vaccine
 
 
 
 
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government
http://www.pharmanews.eu/sanofi-aventis/317-sanofi-pasteur-and-butantan-institute-to-provide-ah1n1-vaccine-to-brazilian-government
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages